參考文獻 |
1. Jemal A, Siegel R, Xu J and Ward E (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60:277-300.
2. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (2012) Staging of prostate caner. Histopathology 60:87-117.
3. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR and Ahmed T (2000) Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer 83:360-365.
4. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312.
5. Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 276-11252-11256.
6. Holcomb IN, Kabakoff RC, Chan B (2000) FIZZ1, a novel cysteine-rich secretated protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 19:4046-4055.
7. Simore ND, Nicuolo FD, Sanguinetti M, Castellani E, D’Asta M, Caforio L, Caruso A (2006) Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. J. Endocrinol. 189:691-699.
8. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C (2006) Adipokine resistin promotes in vitro angiogenesis of human endothelial cell. Cardiocasc. Res. 70:146-157.
9. Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, Kim MK, Kim W, Myung SC (2010) Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int. 108:E77-E83.
10. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI (2010) Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J. Cell Mol. 14:1419-1431.
11. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432.
12. Muoio DM and Lynis DG (2002) Peripheral metabolic actions of leptin. Best Pract. Res. Clin. Endocrinol. Metab. 16:653-666.
13. Onuma M, Bub JD, Rummel TL, Iwamoto Y (2003) Prostate cancer cell-adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J. Biol. Chem. 278:42660-42667.
14. Hoda MR and Poken G (2008) Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int. 102:383-388.
15. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008.
16. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T (1988) A novel potent vasoconstricator peptide produced by cascular endothelial cells. Nature 332:411-415.
17. Grant K and Taylor I (2003) Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer 88:163-166.
18. Ali H, Loizidou M, Dashwood M, Savage F, Sheard C and Taylor I (2000) Stimulation of colorectal cancer cell line growth by ET-1 and its inhibitory by ET(A) antagonists. Gut. 47:685-688.
19. Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Hori S, Handa S, Nakamura Y and Abe K (1990) Production of endothelin in human cancer cell lines. Cancer Res. 50:3257-3261.
20. Rubanyi GM and Polokoff MA (1994) Endothelins:molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Phamacol. Rev. 46:325-425.
21. Nelson J, Bagnato A, Battistini B and Nisen P (2003) The endothelin axis: Emerging role in cancer. Nat. Rev. Cancer 3:110-116.
22. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA and Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1:944-949.
23. Papandreou CN, Usmani B, Geng Y, Boqenrieder T, Freeman R, Wilk S, Finstard Cl, Reuter VE, Powell CT, Scheinberg D, Maqill C, Scher HI, Albino AP and Nanus DM (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med. 4:50-57.
24. Piessevaux J, Lavens D, Peelman F, Tavernier J (2008) The many face of the SOCS box. Cytokine Growth Factor Rev. 19:371-381.
25. Krebs DL and Hilton DJ (2000) SOCS:physiological suppressors of cytokine signaling. J. Cell Sci. 113:2813-2819.
26. Larsen L and Poken C (2002) Suppressor of cytokine signaling: SOCS. APMIS 110:833-844.
27. Jane CT and Rabkin R (2005) Suppressor of cytokine signaling in health and disease. Pediatr. Nephrol. 20:567-575.
28. Motta M, Accornero P, Baratta M (2004) Leptin and prolactin modulate the expression of SOCS-1 in association with interleukin-6 and tumor necrosis factor-α in mammary cells: a role in differentiated secretory epithelium. Regulatory Peptides 121:163-170.
29. Greenhalgh CJ and Hilton DJ (2001) Negative regulation of cytokine signaling. J. Leukoc. Biol. 70:348-356.
30. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA (2005) Activation of SOCS-3 by resistin. Mol. Cell Biol. 25:1569-1575.
31. Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L and Culig Z (2009) Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am. J. Pathol. 5:1921-1930.
32. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W and Culig Z (2006) Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am. J. Pathol. 169:2199-2208.
33. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A and Culig Z (2010) SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signaling. Endocr. Relat. Cancer 17:525-538.
34. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A and Culig Z (2007) Suppressor of cytokine signaling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferative and secretion. Endocr. Relat. Cancer 14:1007-1019.
35. Christopher J. Greenhalgh and Warren S. Alexander (2004) Suppressors of cytokine signaling and regulation of growth hormone action. Growth Horm. IGF Res. 14:200-206.
36. Chang HH, Huang YM, Wu CP, Tang YC, Liu CW, Huamg CH, Ho LT, Wu LY, Kuo YC, Kao YH (2012) Endothelin-1 stimulates suppressor of cytokine signaling-3 gene expression in adipocytes. Gen. Comp. Endocrinol. 178:450-458.
37. Koerner A, Kratzsch J, Kiess W (2005) Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab. 19:525-546.
38. Casey ML, Burd W, MacDonald PC (1992) Massice amounts of immunoreactive endothelin in human seminal fluid. J. Clin. Endoc. Metabol. 74:223-225.
39. Le Brun G, Moldovan F, Aubin P, Cussenot O, Le Duc A and Fiet J (1996) Identification of endothelin receptors in normal and hyperplastic human prostate tissues. Prostate 28:379-384.
40. Nelson JB, Tack KC, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, and Simons JW (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56:663-668.
41. Spinella F, Rosano L, Castro VD, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A (2006) Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol. Cancer Ther. 5:483-492.
42. Spinella F, Rosano L, Decandia S, Castro VD, Albini A, Elia G, Natali PF, Bagnato A (2006) Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp. Biol. Med. 231:1123-1127.
43. Siddiqui IA, Adhami VM, Afaq F, Ahmad N, Mukhtar H (2004) Modulation of phosphatidylinositol-3-kinase/protein kinase B and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J. Cell Biochem. 91:232-242.
44. Vayalil PK and Katiyar SK (2004) Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinase, c-jun and NF-kappaB in human prostate carcinoma DU-145 cells. Prostate 59:33-42.
45. Steenbrugger GJ, Uffelen CJ, Bolt J, Schroder FH (1991) The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J. Steroid Biochem. Mole. Biol. 40:207-214.
46. Kokontis JM, Takakura K, Hay N, Liao S (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54:1566-1573.
47. Kokontis JM, Hay N, Liao S (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12:941-953.
48. Liao S, Kokontis JM, Chuu CP, Hsu S, Fukuchi J, Dang MT, Hiipakka RA. Four stages of prostate cancer: suppression and eradication by androgen and green tea epigallocatechin gallate. In: Li JJ, Li SA, editors. Hormonal carcinogenesis Ⅳ. New York: Springer, 2005:211-220.
49. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC (2011) Androgen as therapy for androgen receptor positive castration-resistant prostate cancer. J. Biomed. Sci. 18:63.
50. Ku HC, Chang HH, Liu HC, Hsiao CH, Lee MJ, Hu YJ, Hung PF, Liu CW, Kao YH (2009) Green tea (-)-epigallocatechin gallate inhibits insulin stimulation of 3T3-L1 preadipocyte mitogenesis via the 67-kDa laminin receptor pathway. Am. J. Physiol. Cell Physiol. 297:C121-C132.
51. Chomczynski P and Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 1:581-585.
52. Fleenor D, Arumugam R, Freemark M (2006) Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressor of cytokine signaling, and regulation of insulin-like growth factor Ⅰ. Horm. Res. 55:101-110.
53. Ishibashi KI, Imamura T, Sharma PM, Ugi S, Olefsky JM (2000) The acute and chronic stimulatory effects of endothelin-1 on glucose uptake are mediated by distinct pathways in 3T3-L1 adipocytes. Endocrinology 141:4623-4628.
54. Imamura T, Ishibashi KI, Dalle S, Ugi S, Olefsky JM (1999) Endothelin-1-induced GLUT4 translocation is mediated via Gaq/11 protein and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J. Biol. Chem. 274:33691-33695.
55. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z (2009) Down-regulation of suppressor of cytokine signling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res. 69:7375-7384.
56. Lee IT, Lin CC, Lee CY, Hsieh PW, Yang CM (2013) Protective effects of (-)-epigallocatechin-3-gallate against TNF-α-induced lung inflammation via ROS-dependent ICAM-1 inhibition. J. Nutr. Biochem. 24:124-136.
57. Tokuda H, Takai S, Hanai Y, Nishiwaki RM, Hosoi T, Harada A, Ohta T, Kozawa O (2007) (-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: inhibition of p44/p42 MAP kinase activation. FEBS Lett. 581:1311-1316.
58. Reiter C, Kim JA, Quon MJ (2010) Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: role for AMP-activated protein kinase, akt, and foxo1. Endocrinology 151:103-114.
59. Ginzinger DG (2002) Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp. Hematol. 30:503-512.
60. Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj M, Rao PN (2008) Differential effects of leptin on the invasive potential of androgen-dependent and –independent prostate carcinoma cells. J. Biomed. Biotechnol. 2008:163902. |